592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
暂无分享,去创建一个
R. Coleman | H. Denys | T. Van Gorp | M. Method | J. Konner | A. Oaknin | D. Lorusso | U. Matulonis | M. Birrer | F. Zhu | P. Harter | N. Colombo | B. Esteves | M. Romeo Marin | D. O’malley | S. Pignata | C. Murphy | Y. Tu | K. Moore